Cargando…

Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?

OBJECTIVE: The aim of this study was to investigate an independent correlation between high sensitivity C-reactive protein (hs-CRP) and glycated haemoglobin (HbA1c) on one side and between hs-CRP and arterial pressure in well glucose controlled type 2 diabetics on the other side. RESULTS: The mean o...

Descripción completa

Detalles Bibliográficos
Autores principales: Patrice, Nzogang K., Martial, Donkeng J., Bruno, Telefo P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591512/
https://www.ncbi.nlm.nih.gov/pubmed/28886725
http://dx.doi.org/10.1186/s13104-017-2785-4
_version_ 1783262728106803200
author Patrice, Nzogang K.
Martial, Donkeng J.
Bruno, Telefo P.
author_facet Patrice, Nzogang K.
Martial, Donkeng J.
Bruno, Telefo P.
author_sort Patrice, Nzogang K.
collection PubMed
description OBJECTIVE: The aim of this study was to investigate an independent correlation between high sensitivity C-reactive protein (hs-CRP) and glycated haemoglobin (HbA1c) on one side and between hs-CRP and arterial pressure in well glucose controlled type 2 diabetics on the other side. RESULTS: The mean of HbA1c was 6.37% in this study and 70.10% of participants had an HbA1c less than 7%. A positive correlation between hs-CRP and HbA1c was found in the current study (r = 0.232; P = 0.043) and we observed a decrease of 0.79% of HbA1c of the participants when their hs-CRP was less than 1 mg/l compared to that of the participants who had hs-CRP more than 1 mg/l (5.75 ± 1.25% VS 6.54 ± 1.42% P value = 0.04 Student). No correlation was found between hs-CRP and arterial pressure in this study. These results could justify the perspective use of anti-inflammatory drugs in the management of T2D. However the presence of participants with HbA1c levels greater than 7% makes plausible the influence of confounding factors on the observed correlations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13104-017-2785-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5591512
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55915122017-09-13 Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? Patrice, Nzogang K. Martial, Donkeng J. Bruno, Telefo P. BMC Res Notes Research Note OBJECTIVE: The aim of this study was to investigate an independent correlation between high sensitivity C-reactive protein (hs-CRP) and glycated haemoglobin (HbA1c) on one side and between hs-CRP and arterial pressure in well glucose controlled type 2 diabetics on the other side. RESULTS: The mean of HbA1c was 6.37% in this study and 70.10% of participants had an HbA1c less than 7%. A positive correlation between hs-CRP and HbA1c was found in the current study (r = 0.232; P = 0.043) and we observed a decrease of 0.79% of HbA1c of the participants when their hs-CRP was less than 1 mg/l compared to that of the participants who had hs-CRP more than 1 mg/l (5.75 ± 1.25% VS 6.54 ± 1.42% P value = 0.04 Student). No correlation was found between hs-CRP and arterial pressure in this study. These results could justify the perspective use of anti-inflammatory drugs in the management of T2D. However the presence of participants with HbA1c levels greater than 7% makes plausible the influence of confounding factors on the observed correlations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13104-017-2785-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-08 /pmc/articles/PMC5591512/ /pubmed/28886725 http://dx.doi.org/10.1186/s13104-017-2785-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Note
Patrice, Nzogang K.
Martial, Donkeng J.
Bruno, Telefo P.
Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
title Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
title_full Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
title_fullStr Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
title_full_unstemmed Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
title_short Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
title_sort is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
topic Research Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591512/
https://www.ncbi.nlm.nih.gov/pubmed/28886725
http://dx.doi.org/10.1186/s13104-017-2785-4
work_keys_str_mv AT patricenzogangk isitasupplementarybenefittouseantiinflammatoryagentsinthetreatmentoftype2diabetes
AT martialdonkengj isitasupplementarybenefittouseantiinflammatoryagentsinthetreatmentoftype2diabetes
AT brunotelefop isitasupplementarybenefittouseantiinflammatoryagentsinthetreatmentoftype2diabetes